How Similar Are Biosimilars? A Look Into the Future With Biosimilars in Multiple Sclerosis

Four advanced practice providers discuss biosimilars and how they can play an important role in healthcare.

Clinical experts discuss differences and similarities between biosimilars and reference products.

Amy Perrin Ross, APN, Patricia Melville, NP-C, Aliza Ben-Zacharia, PhD, DNP, ANP-BC, and John Kramer, PA-C discuss approval process of biosimilars.

Amy Perrin Ross, APN, Patricia Melville, NP-C, and Aliza Ben-Zacharia, PhD, DNP, ANP-BC discuss importance of evaluating immunogenicity of biosimilars.

Advanced practice providers discuss potential cost savings with biosimilars and biosimilar use in multiple sclerosis.

Amy Perrin Ross, APN, Patricia Melville, NP-C, Aliza Ben-Zacharia, PhD, DNP, ANP-BC, and John Kramer, PA-C discuss natalizumab biosimilar (biosim-NTZ) PB006 phase 3 Antelope study.

Aliza Ben-Zacharia, PhD, DNP, ANP-BC and Amy Perrin Ross, APN discuss differences between biologic and biologic natalizumab phase 3 trials.

John Kramer, PA-C, Patricia Melville, NP-C, and Amy Perrin Ross, APN identify challenges in accessing biosimilars in clinical practice.

Amy Perrin Ross, APN, Aliza Ben-Zacharia, PhD, DNP, ANP-BC, and John Kramer, PA-C share strategies for implementing biosimilars in clinical practice.

Advanced practice providers share how to discuss biosimilars with patients and what resources might be useful for education on biosimilars.

Amy Perrin Ross, APN, Patricia Melville, NP-C, Aliza Ben-Zacharia, PhD, DNP, ANP-BC, and John Kramer, PA-C share their advice for facilitating uptake of biosimilars in clinical practices.